A Randomised, Double-blind, Double-dummy, Parallel-group, Multicenter, Phase IIb Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Days With Pain in Young Adults With Sickle Cell Disease
Phase of Trial: Phase II
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Ticagrelor (Primary)
- Indications Pain; Sickle cell anaemia
- Focus Therapeutic Use
- Acronyms Hestia2
- Sponsors AstraZeneca
- 12 Dec 2016 Status changed from active, no longer recruiting to completed.
- 05 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Nov 2016.
- 05 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Nov 2016.